ImpediMed Limited (ASX:IPD)
has announced an at-home study in lymphoedema with its next generation device will soon commence in the US.
The study will be run in conjunction with Vanderbilt University School of Nursing, with shipment of the company’s SOZO™ device to the US underway.
The at-home study will be conducted on cancer survivors, and will monitor fluid levels in the body for early detection of sub-clinical lymphoedema.
CEO Richard Carreon has indicated the at-home pilot study will complement the in-clinic programs for its SOZO device.
Share in ImpediMed Limited (ASX:IPD)
last traded 1.38% higher at $0.735.